iStock_000019968480MediumAccording to FDANews.com, “A 747-patient, multisite study in the U.S. showed promising results for Medtronic’s CoreValve, a transcatheter aortic valve-replacement device. Patients who used the valve exhibited a lower stroke rate and a higher survival rate after two years, compared with control-group patients.”  For more information on this trial, please visit:  http://www.fdanews.com/articles/170375-medtronics-corevalve-bests-surgery-at-two-year-mark